[China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)

Announced Date: 2023-11-06 (November 6, 2023)

Asset Name: PM8002 (BNT327)

Licensor (Seller): Zhuhai Biotheus Inc (China)

Licensee (Buyer): BioNTech

.

Asset Modality: BsAbs (Bispecific antibody)

Asset Target: PD-L1 and VEGF-A

Potential Indication: advanced solid tumors

Current Stage:Phase 2 studies in China

.

Scope of Authority:

Under the agreement of 2023,

BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China,

whereas Biotheus retains the rights to exploit PM8002 in Greater China. 

.

Payment Detail:

Biotheus will receive:

Upfront payment of $55 million,

Development, regulatory and sales milestone payments potentially totalling over $1 billion.

Tiered royalties on potential future product sales.

.

Link:

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications (prnewswire.com)

.

Chinese Name of Biotheus, 普米斯